Meeting
2011 ASCO Annual Meeting
A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group.
Authors
S. I. Jalal
Indiana University Simon Cancer Center, Indianapolis, IN
S. I. Jalal , J. A. Bufill , G. A. Masters , N. Somaiah , K. Koneru , J. McClean , R. E. Sanborn , J. Wu , Z. Yu , L. H. Einhorn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Local-regional and Adjuvant Therapy/Small Cell
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00890955
Citation
J Clin Oncol 29: 2011 (suppl; abstr 7082)
Abstract #
7082
Poster Bd #
29B
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: HOG LUN 07-130.
First Author: Shadia Ibrahim Jalal
Poster
2024 ASCO Annual Meeting
Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.
First Author: Justin M. Watts
Poster
2023 ASCO Annual Meeting
Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.
First Author: Justin M. Watts
Poster
2023 ASCO Annual Meeting
Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients.
First Author: John B. Liao